Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R. Furman(Cornell University), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Raquel Izumi, Deborah M. Stephens(University of North Carolina at Chapel Hill), Tamara Lezhava(AstraZeneca (United States)), John M. Pagel(University of Washington), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Simon Rule(AstraZeneca (United Kingdom)), Matthew Streetly(King's College - North Carolina), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Marshall Baek(AstraZeneca (United States)), Ahmed Hamdy(Pharmacyclics (United States)), Clare Sun(National Heart Lung and Blood Institute), Martin J.S. Dyer(University of Leicester), Nataliya Chernyukhin(AstraZeneca (United States)), Paolo Ghia(Vita-Salute San Raffaele University), Michael Wang(St. Joseph Health System), Wojciech Jurczak(Jagiellonian University), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John C. Byrd(University of Cincinnati), Priti Patel(AstraZeneca (United States)), Susan O’Brien(University of California, Irvine)
Cited by 62
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k